Login to Your Account



Ceptaris Gains FDA Nod; Inks $250M M&A Deal with Actelion

By Nuala Moran
Staff Writer

Wednesday, August 28, 2013
LONDON – Barring the dotting of a few i’s and crossing of a few t’s, the $250 million acquisition of Ceptaris Therapeutics Inc. by the Swiss biotech Actelion Ltd. is ready to go ahead, after Ceptaris announced FDA approval of its only product, Valchlor.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription